Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers
Eli Lilly and Company announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.
Eli Lilly and Company announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and transparency of clinical trial results with researchers around the world.
The new portal, www.clinicalstudydatarequest.com, differs from previous Lilly data-sharing sites in that access will only be granted after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent scientific review panel.
As part of Lilly's commitment to open access and transparency, the company established its own web site in January 2014 to facilitate researchers' requests for data from interventional clinical trials for approved medicines and indications. However, this website was an interim solution. Lilly will replace the current web site, www.lillyclinicalstudydata.com, with the newly announced www.clinicalstudydatarequest.com.
Lilly also provides information on and links to information about our clinical studies on www.LillyTrials.com. The website includes results of all Lilly-sponsored Phase II, Phase III and Phase IV clinical trials as well as observational trials of Lilly-marketed products conducted anywhere in the world that were initiated on or after October 15, 2002.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
